We are developing products and researching novel therapies that have potential applications across the healthcare spectrum, including hemostasis, targeted drug delivery, and regenerative medicine. We also support animal health through our veterinary subsidiary BodeVet®.
Platelet-based hemostatics can play a key role in treating bleeding in hospitalized patients and prehospital situations to help prevent hemorrhage-associated death. Cellphire is developing products that can be routinely available at all levels of care and to all providers once approved by the U.S. Food and Drug Administration.
Hemorrhage is the leading cause of U.S. civilian death from trauma and military deaths on the battlefield (Shackelford, 2017).
Trauma deaths from hemorrhage could be reduced by 36 percent, or over 50,000 saved lives, in the United States per year with balanced early transfusion of blood products, including platelets (Drake, 2020).
Thrombocytopenic patients who have low platelet counts sometimes bleed despite receiving routine platelet transfusions to increase their platelet count. These patients need a safe, reliable, and easy to use platelet-based hemostatic that will quickly stop breakthrough bleeds.
BodeVet®, a wholly owned subsidiary of Cellphire, is solving the unmet needs of companion and exotic animals for transfusion medicine and regenerative therapies. The company uses Cellphire's technology to develop its veterinary medicines, including StablePlate RX®, a canine platelet-derived hemostatic.
OneHealth. An Initiative to Save the Lives of Humans and Animals Cellphire and BodeVet® are working together to learn from and use veterinary clinical data to advance the development of human and animal therapeutics.
We are applying our technology to expand the potential use of platelets as carriers for targeted delivery of drugs and other biomolecules.
Loaded Thrombosomes or CPP could circulate within the body and target a bleeding area (brain injury, bleeding tumor, etc.). They then deliver their cargo (drug) through platelet release mechanisms as well as cell fusion. The objective of using loaded Thrombosomes or CPP is to deliver a high concentration of the drug at the target site (e.g., tumor or organ) in order to eliminate the side effects by highly reducing the presence of the drug in the general circulation of the patient.
Treatment with anticoagulants and antiplatelet agents is common for patients with cardiac and vascular diseases. There has been a significant increase in the use of these agents for primary prevention of stroke and heart disease. Patients taking these drugs are at a greater risk of bleeding from accidents or if they need emergency surgery.
We are exploring next generation platelet products to be able to stop bleeding in the presence of anticoagulants and anti-platelet drugs and have preliminary data to support reversal of platelet COX-1 antagonists (aspirin, NSAIDS), P2Y12 antagonists (clopidogrel) and GPIIb/IIIIa antagonists (abciximab); warfarin and heparin general anticoagulants; and direct thrombin and factor Xa inhibitors.
Cellphire is developing regenerative medicine therapeutics that have a range of potential applications, including: